<DOC>
	<DOCNO>NCT02077777</DOCNO>
	<brief_summary>The purpose study obtain `` vivo '' confirmation mesalazine induces gene expression μ-protocadherin related gene colon mucosa , demonstrate `` vitro '' experiment . .</brief_summary>
	<brief_title>Chemopreventive Action Mesalazine Colorectal Cancer : Pilot Study `` Vivo '' Evaluation Molecular Effects β-catenin Signaling Pathway .</brief_title>
	<detailed_description>Pilot Trial , single-blind , parallel group biopsy specimens healthy colon mucosa patient precancerous lesion colon rectum ( adenoma ) treat mesalazine .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patients precancerous colorectal lesion ( polypoid nonpolypoid adenoma ) need endoscopic exam control 3 month removal lesion ( determine basis morphological histological characteristic lesion removal technique ) Ability willingness adhere study regimen Written inform consent The following inclusion criterion delete accord Amendment n. 01 approve Ethical Committee 19/dec/2014 : diverticular disease/diverticular colitis ; The rationale change presence diverticular disease/diverticular colitis contribute definition trial primary endpoint represent critical point patient selection impact duration conduction study . Patients therapy Aspirin ( &gt; 100 mg/die ) FANS Inflammatory bowel disease ( IBD ) Hypersensitivity Mesalazine . Pregnant nursing ( lactate ) woman Patients belong category n. 4 ASA physical status classification system contraindication mesalazine therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>mesalazine</keyword>
	<keyword>colon</keyword>
	<keyword>cancer</keyword>
</DOC>